Glaucoma

• Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA® treatment is discontinued.
• Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes, and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA® treatment is discontinued.
• Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions.
• Tell your doctor immediately about any change in your eye, any eye condition that develops, any sudden change in your vision, any eye side effects, or if you have eye surgery.
• Remove contact lenses before putting VYZULTA® in your eyes. Lenses may be reinserted 15 minutes later.
• If you are using other eye drops in addition to VYZULTA®, wait 5 minutes between using each type of eye drop.
• The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information for VYZULTA®.

• TIMOPTIC® in OCUDOSE® should not be used by patients with: asthma, or a history of asthma; severe chronic obstructive pulmonary disease, a lung disease commonly known as COPD; sinus bradycardia (an usually slow heartbeat); severe atrioventricular block (a heart condition that causes sudden bouts of unconsciousness); heart failure or reduced heart function or shock, or allergy to any ingredient of the product.
• Tell your eyecare provider (ECP) about any health conditions you may have and use TIMOPTIC® in OCUDOSE® as directed. 
• This drug is called a beta-adrenergic blocking agent, or beta blocker. Although it is an eye drop, it enters the bloodstream like beta blockers taken orally (by mouth). The same side effects for oral beta blockers have also been reported with TIMOPTIC® in OCUDOSE® eye drops. These include severe lung or heart reactions, including death.
• Depression of the heart muscle with beta blockers over a period of time can lead to heart failure. At the first sign or symptom of heart failure, your ECP should stop your TIMOPTIC® in OCUDOSE®.
• If you have COPD you should not receive beta blockers, including Preservative-free TIMOPTIC® in OCUDOSE®.
• Be sure to tell your ECP that you are using TIMOPTIC® in OCUDOSE® if you are going to have surgery. Your ECP may gradually reduce your dose before surgery.
• If you have diabetes or low blood sugar, beta blockers can mask the signs and symptoms of acute low blood sugar.
• If you have hyperthyroidism (high thyroid levels), you should not stop your beta blocker quickly as this may mask some symptoms of thyroid storm (large amount of thyroid hormone released quickly).
• Your ECP may consider an alternative medicine if you develop symptoms of reduced blood flow to the brain following initiation of therapy with Preservative-free TIMOPTIC® in OCUDOSE®.
• Detachment of blood vessels in the eye after a procedure to drain excess fluid from the eye has been reported with the use of TIMOPTIC® in OCUDOSE®.
• TIMOPTIC® in OCUDOSE® should not be used alone in the treatment of angle-closure glaucoma.
• If you have a history of severe allergic reactions, while taking beta blockers you may not respond to the usual dose of epinephrine used to treat those reactions.
• Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis (weakness of skeletal muscles).
• To avoid contamination, use this product right away after opening and throw away the unit with the leftover medicine. Do not reuse the unit.
• The most frequently reported side effects (seen in about 1 out of 8 patients) have been burning and stinging while putting the drops in the eyes. 

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information for TIMOPTIC® in OCUDOSE®.

• ISTALOL® ophthalmic solution should not be used by patients with: asthma, or a history of asthma; severe chronic obstructive pulmonary disease, a lung disease commonly known as COPD; sinus bradycardia (an unusually slow heartbeat); severe atrioventricular block (a heart condition that causes sudden bouts of unconsciousness); heart failure or reduced heart function or shock, or allergy to any component of the product.
• Tell your eye care professional (ECP) about any health conditions you may have and use ISTALOL® as directed.
• This drug is called a beta-adrenergic blocking agent, or beta blocker. Although it is an eye drop, it enters the bloodstream like beta blockers taken orally (by mouth). The same side effects seen with oral beta blockers have also been reported with the use of eye drops. These include severe lung or heart reactions, including death.
• Depression of the heart muscle with beta blockers over a period of time can lead to heart failure. At the first sign or symptom of heart failure, your ECP should stop your ISTALOL®.
• If you have COPD, you should not receive beta blockers, including ISTALOL®.
• If you have a history of severe allergic reactions, while taking beta blockers you may not respond to the usual dose of epinephrine used to treat those reactions.
• Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis (weakness of skeletal muscles).
• If you have diabetes or low blood sugar, beta blockers can mask the signs and symptoms of acute low blood sugar.
• If you have hyperthyroidism (high thyroid levels), you should not stop your beta blocker quickly as this may mask some symptoms of thyroid storm (large amount of thyroid hormone released quickly).
• Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions.
• If you are using other eye drops in addition to ISTALOL®, wait 5 minutes between using each type of eye drop.
• Remove contact lenses before putting ISTALOL® in your eyes. Lenses may be reinserted 15 minutes later.
• Be sure to tell your ECP that you are using ISTALOL® if you are going to have surgery. Your ECP may gradually reduce your dose before surgery.
• ISTALOL® should not be used alone in the treatment of angle-closure glaucoma.
• Your ECP may consider an alternative medicine if you develop symptoms of reduced blood flow to the brain following initiation of therapy with ISTALOL®.
• Detachment of blood vessels in the eye after a procedure to drain excess fluid from the eye has been reported with the use of timolol.
• The most frequently reported side effects (seen in 38% of patients) have been burning and stinging while putting the drops in the eyes. Additional side effects reported in 4 to 10% of patients included blurred vision, cataract, eye redness, headache, high blood pressure, infection, itching and decreased vision.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information for ISTALOL®, including a complete listing of the Warnings and Precautions.